Results showed that Fused 64CuCl2-PET/MRI had the highest DR,
compared with all the other fusion and non-fusion techniques,
in every site of recurrence (local,
lymph-node metastases and bone metastases),
as shown in Table 1.
A significant difference was found between the DRs of Fused-64CuCl2-PET/MRI (88%) and Fused-18F-Choline-PET/MRI (68%; p=0.002).
The DR of Fused-64CuCl2-PET/MRI (88%) was higher than 64CuCl2-PET/CT (82%),
but the difference was not significant (p=0.25).
In the patient-based analysis,
the DRs of 64CuCl2-PET/MRI and mMRI were not significantly different (p=0.02).
Interestingly,
on considering PSA value,
64CuCl2-PET/MRI had a higher DR than 18F-Choline-PET/MRI in Patients with PSA <4 ng/ml: in particular,
DRs of 64CuCl2-PET/MRI and 18F-Choline-PET/MRI were 82% and 55% for PSA level <1 ng/ml,
88% and 65% for PSA 1.1-2.0,
91% and 64% for PSA 2.1-4.0,
respectively; when PSA level was >4 ng/ml the DRs were equivalent (91%).
The DR of Fused-64CuCl2-PET/MRI and Fused-18F-Choline-PET/MRI were higher than 64CuCl2-PET/CT and 18F-Choline-PET/CT in Patients with PSA level <2ng/ml.
At PSA levels < 2.0 Fused-64CuCl2-PET/MRI and Fused-18F-Choline-PET/MRI showed an increased DR if compared,
respectively,
with 64CuCl2-PET/CT and 18F-Choline-PET/CT.
(Table 3)
Lesion-based-analysis (LBA)
64CuCl2-PET/MRI detected 113/119 lesions (95%),
in particular,
100% of local recurrence,
95% of lymph-node metastases and 79% of bone metastases.
DRs of Fused-64CuCl2-PET/MRI were higher than Fused-18F-Choline-PET/MRI in each site of recurrence (all positive patients,
local,
lymph-nodes),
except for bone localizations where the two DRs were comparable,
respectively 79% (11/14) and 71% (10/14).
A significant difference in local recurrence was found between DR of Fused-64CuCl2-PET/MRI and Fused-18F-Choline-PET/MRI (100% vs 48%; p<0,0001).
Fused 64CuCl2 PET/MRI had the highest DRs compared to all the other techniques in the detection of lymph-node recurrence (58/61,
95%).
Multiparametric MRI showed the highest DR in the detection of bone metastases (100%).
Results are shown in Table 2.